MX2017013390A - Método para el tratamiento de cáncer pulmonar. - Google Patents

Método para el tratamiento de cáncer pulmonar.

Info

Publication number
MX2017013390A
MX2017013390A MX2017013390A MX2017013390A MX2017013390A MX 2017013390 A MX2017013390 A MX 2017013390A MX 2017013390 A MX2017013390 A MX 2017013390A MX 2017013390 A MX2017013390 A MX 2017013390A MX 2017013390 A MX2017013390 A MX 2017013390A
Authority
MX
Mexico
Prior art keywords
fra
patient
lung cancer
level
methods
Prior art date
Application number
MX2017013390A
Other languages
English (en)
Spanish (es)
Inventor
John O'shannessy Daniel
Original Assignee
Morphotek Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphotek Inc filed Critical Morphotek Inc
Publication of MX2017013390A publication Critical patent/MX2017013390A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2017013390A 2015-04-17 2016-04-14 Método para el tratamiento de cáncer pulmonar. MX2017013390A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562149184P 2015-04-17 2015-04-17
PCT/US2016/027497 WO2016168440A1 (en) 2015-04-17 2016-04-14 Methods for treating lung cancer

Publications (1)

Publication Number Publication Date
MX2017013390A true MX2017013390A (es) 2018-06-13

Family

ID=55809240

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013390A MX2017013390A (es) 2015-04-17 2016-04-14 Método para el tratamiento de cáncer pulmonar.

Country Status (13)

Country Link
US (1) US20180125970A1 (enExample)
EP (1) EP3283886B1 (enExample)
JP (1) JP2018516244A (enExample)
KR (1) KR20170137848A (enExample)
CN (1) CN107624071A (enExample)
AU (1) AU2016248222A1 (enExample)
BR (1) BR112017022320A2 (enExample)
CA (1) CA2983126A1 (enExample)
IL (1) IL255079A0 (enExample)
MX (1) MX2017013390A (enExample)
RU (1) RU2718780C9 (enExample)
SG (1) SG11201708546UA (enExample)
WO (1) WO2016168440A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2607444C (en) * 2005-04-22 2015-03-10 Morphotek, Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
WO2015186823A1 (ja) * 2014-06-06 2015-12-10 協和発酵キリン株式会社 Ｆｏｌｒ１標的薬および葉酸代謝拮抗剤によるがん患者のための治療方法並びに医薬
EP3544999A1 (en) 2016-11-23 2019-10-02 Eisai R&D Management Co., Ltd. Anti-folate receptor alpha antibodies and uses thereof
AU2019236091B2 (en) 2018-03-13 2025-06-05 Phanes Therapeutics, Inc. Anti-folate receptor 1 antibodies and uses thereof
AU2019291307B2 (en) * 2018-06-18 2024-04-04 Fundacio Privada Institucio Catalana de Recerca i Estudis Avancats Combination of LIF inhibitors and platinum-based antineoplastic agents for use in treating cancer
CN110221052B (zh) * 2019-06-17 2022-09-23 昆山德诺瑞尔生物科技有限公司 Ppfibp1蛋白在制备肝癌术后预后评估试剂盒中的应用
KR20240162086A (ko) * 2022-03-11 2024-11-14 아스트라제네카 아베 항-FRα 항체-약물 접합체 치료법에 대한 점수 산정 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3101034A1 (en) 2004-02-12 2016-12-07 Morphotek, Inc. Monoclonal antibodies that specifically bind to folate receptor alpha
CA2607444C (en) * 2005-04-22 2015-03-10 Morphotek, Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
GB0718167D0 (en) * 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
MX343607B (es) 2010-11-05 2016-11-11 Morphotek Inc Receptor alfa de folato como marcador de diagnóstico y pronóstico para cánceres que expresan receptor alfa de folato.
SI2731972T1 (en) * 2011-07-15 2018-04-30 Eisai R&D Management Co., Ltd. Anti-folate receptor alpha antibodies and uses thereof

Also Published As

Publication number Publication date
SG11201708546UA (en) 2017-11-29
CA2983126A1 (en) 2016-10-20
RU2017136863A (ru) 2019-05-17
IL255079A0 (en) 2017-12-31
JP2018516244A (ja) 2018-06-21
WO2016168440A1 (en) 2016-10-20
BR112017022320A2 (en) 2018-07-24
CN107624071A (zh) 2018-01-23
RU2017136863A3 (enExample) 2019-08-21
AU2016248222A1 (en) 2017-11-09
EP3283886B1 (en) 2020-01-15
RU2718780C9 (ru) 2020-07-08
RU2718780C2 (ru) 2020-04-14
EP3283886A1 (en) 2018-02-21
KR20170137848A (ko) 2017-12-13
US20180125970A1 (en) 2018-05-10

Similar Documents

Publication Publication Date Title
MX2017013390A (es) Método para el tratamiento de cáncer pulmonar.
MX2023010805A (es) Metodos terapeuticos y de diagnostico para el cancer.
MX2021009682A (es) Biomarcadores de cinasa 2 dependientes de ciclinas y sus usos.
MX2022006589A (es) Predictor de respuesta de platino pan-cancer.
MX2016010237A (es) Metodos de tratamiento de enfermedad de alzheimer.
MX2018010361A (es) Métodos terapéuticos y de diagnóstico para el cáncer.
MX2017008421A (es) Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga.
PH12020551683A1 (en) Biomarkers for graft-versus-host disease
MX2015011362A (es) Metodo para el pronostico y tratamiento de metastasis de cancer.
MX2019010150A (es) Uso de biomarcadores en la identificacion de pacientes con cancer que seran sensibles al tratamiento con un inhibidor de prmt5.
MX2017011486A (es) Métodos de detección y cuantificación de il-13 y sus usos en el diagnóstico y tratamiento de enfermedades asociadas a th2.
BR112014018331A8 (pt) Biomarcadores e terapias combinadas usando vírus oncolítico e imunomodulação
MX392774B (es) Uso de paneles de genes mutantes de fgfr en la identificacion de pacientes con cancer que responderán al tratamiento con un inhibidor fgfr
BR112016007864A2 (pt) método para a prognose e tratamento de metástase de câncer
MX2017006242A (es) Determinacion de niveles de glicosaminoglicanos mediante espectrometria de masas.
PE20160192A1 (es) Composiciones y metodo para tratar condiciones asociadas con el complemento
MX2024001734A (es) Metodo de modificacion de diferenciacion e inmunidad de macrofagos.
CL2020001936A1 (es) Métodos para el tratamiento de la atrofía muscular espinal.
BR112019025056A2 (pt) Inibidores de fgfr2 para o tratamento de colangiocarcinoma
CO2020008863A2 (es) Biomarcadores de tolerancia inmunitaria inducida por metotrexato
MX2025004103A (es) Metodos de identificacion de pacientes con posibilidad de beneficiarse de un tratamiento con un inhibidor de la telomerasa
BR112016017926A2 (pt) ensaio para detectar periostina humana
BR112017012287A2 (pt) uso de inibidores pan-fgfr e método de identificação de pacientes com câncer elegíveis para tratamento com um inibidor pan-fgfr
MX2018009112A (es) Metodo para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cancer mediante la medicion del nivel de un biomarcador plasmatico.
MX2020003565A (es) Variantes de cornulina (crnn) y sus usos.

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: EISAI INC.